Objective:

The article examines the objective, findings, and clinical context described in Stuart Therapeutics Expands Corneal Repair Pipeline.

Approach:

• Regulatory update: The company submitted an amendment to its investigational new drug application to the FDA for a proof-of-concept study of ST-100 in corneal wound healing.
• Investigational therapy: ST-100 is a collagen mimetic peptide developed with Stuart’s PolyCol™ platform and is designed to target damaged helical collagen in the ocular extracellular matrix.
• Planned studies: Stuart plans a phase 2 trial in the second half of 2027 involving corneal wounds related to surgery, trauma, ulcers, and chemical burns.

Key Findings:

• The proposed corneal wound-healing program is ST-100’s first expansion beyond dry eye disease.
• In phase 2 and initial phase 3 dry eye studies involving more than 250 patients, the company reported improvements in corneal fluorescein staining and several symptom-related outcomes; some benefits were observed as early as two days after treatment.
• The initial phase 3 dry eye trial, reported in June 2025, did not meet its primary endpoint for a statistically significant improvement in Schirmer’s tear test responder rates versus vehicle.
• Stuart plans another phase 3 registration trial for dry eye disease in early 2027.

Interpretation:

ST-100’s efficacy for corneal wound healing has not been established. The proposed studies are intended to assess whether targeting damaged collagen can support epithelial and stromal repair after corneal injury.

Limitations:

• The corneal wound-healing program is planned; no results from these studies are reported.
• The initial phase 3 dry eye trial did not meet its primary endpoint.

Conclusion:

The company is pursuing clinical evaluation of ST-100 for corneal wounds while continuing development for dry eye disease.

Sources:

• Stuart Therapeutics